At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prospective, Randomised, Open, Blinded-endpoint Study of Torasemide Prolonged Release vs Furosemide to Evaluate the Efficacy on Myocardial Fibrosis in Patients With Heart Failure
In Brief
A Phase 4 clinical trial evaluating Torasemide Prolonged Release and Furosemide for Congestive Heart Failure. Completed, enrolled 142 participants across 23 sites.
Detailed Summary
Torasemide is a loop diuretic (pyridine-sulfonylurea)with a wide experience in the treatment of oedema associated to heart failure, kidney or liver disease and either in the treatment of arterial hypertension (alone or combined with other anti-hypertensive drugs). It has been developed a new formulation of Torasemide (Torasemide prolonged release). The aim of this trial is to study the effects of Torasemide prolonged released in comparison with furosemide, in the reduction of myocardial fibrosis in patients with chronic heart failure (Class II-IV of the New York Heart Association Classification.
Study Details
Timeline
Interventions
Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months